DBP International AB: a new patent for SA-033 is granted in USA
Double Bond Pharmaceutical's second patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in the United States. Patent approval provides protection for the treatment method and the design of composition for DBP's front-line product SA-033."We are very pleased because it is an important milestone in the development of balanced product pipeline", - comments Igor Lokot, CEO of DBP.More about SA-033: SA-033 is the first drug candidate that DBP has developed using its innovative